Clozapine for Severe Treatment-Resistant Disruptive Behaviors in Youth with Autism Spectrum Disorder: A Prospective Real-World Interventional Study
Journal of Child and Adolescent Psychopharmacology · 01.12.2026 · 36 (10) · 617-630
DOI: 10.1177/10445463261467155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 23.07.2026. Verfasst von André Luiz Schuh Teixeira da Rosa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program of Psychiatry and Behavioral Sciences, Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, Autism Spectrum Disorder, Problem Behavior. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil, Hospital de Clínicas de Porto Alegre.
Abstract (Originalsprache)
Objective
Severe disruptive behaviors in youth with autism spectrum disorder (ASD) frequently persist despite conventional treatments, contributing to functional impairment. Although clozapine has antiaggressive properties, evidence guiding its use in treatment-resistant cases in autistic youth remains predominantly observational and retrospective. This study aimed to evaluate systematically and prospectively the effectiveness and safety of clozapine for treatment-resistant disruptive behaviors (TR-DB) in youth with ASD under routine conditions.
Methods
This single-arm, open-label trial enrolled participants aged 10–17 with ASD. Inclusion required TR-DB after ≥2 antipsychotic trials and a Clinical Global Impression–Severity score ≥5. Following flexible titration, clozapine was maintained for 12 weeks. The primary outcome was change on the caregiver-rated Aberrant Behavior Checklist–Irritability (ABC-I). Secondary measures included global improvement, autism symptom severity, adaptive behavior, and caregiver quality of life. Response was defined as ≥30% ABC-I reduction plus a CGI–Improvement (CGI-I) of 1 to 2; remission required ≥80% ABC-I reduction and a CGI-I of 1.
Results
Thirty-one participants initiated clozapine treatment (mean age 13.4 years; 90.3% male), and 28 completed the trial. ABC-I scores decreased from 32.0 ± 7.7 to 7.4 ± 5.1 (Cohen’s d z −2.5; p < 0.001). Overall, 83.9% responded, and 38.7% remitted. Global severity improved from 6.1 ± 0.6 to 3.8 ± 1.6 ( p < 0.001). Significant improvements were observed in daily living skills, caregiver quality of life, and reduced polypharmacy. Adverse drug reactions were mostly mild-to-moderate; however, metabolic changes comprised significant weight gain and triglyceride elevation (both p < 0.05). Serious events included seizures ( n = 4) and pneumonia ( n = 1).
Conclusions
Clozapine was associated with robust, rapid TR-DB reductions and high retention in autistic youth. However, safety risks mandate rigorous monitoring. Controlled trials are needed to confirm efficacy and refine the benefit–risk profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Program of Psychiatry and Behavioral Sciences, Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Division of Child and Adolescent Psychiatry, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
- School of Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
- Child Neurology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
- Department of Statistics, Institute of Mathematics and Statistics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Biostatistics and Data Analysis Unit, Research Board, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
ORCID-Profile: André Luiz Schuh Teixeira da Rosa, Gabriela Bezerra Sorato, Felipe Manjabosco, Lucas Dellazari, Érica Bonganhi de Bem, Arthur Bezerra Falcão, Ana Júlia Limberger Nedel, Marina Ribeiro Barreto da Costa, Olivia Sorato Bezerra, Rogério Boff Borges, Ana Soledade Graeff-Martins
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil
- Hospital de Clínicas de Porto Alegre
Zitieren
APA
da Rosa, A. L. S. T., Sorato, G. B., Manjabosco, F., Dellazari, L., de Bem, É. B., Falcão, A. B., Cia, L. O., Nedel, A. J. L., da Costa, M. R. B., Bezerra, O. S., Borges, R. B., Rohde, L. A., & Graeff-Martins, A. S. (2026). Clozapine for Severe Treatment-Resistant Disruptive Behaviors in Youth with Autism Spectrum Disorder: A Prospective Real-World Interventional Study. Journal of Child and Adolescent Psychopharmacology, 36(10), 617-630. https://doi.org/10.1177/10445463261467155
Vancouver
da Rosa ALST, Sorato GB, Manjabosco F, Dellazari L, de Bem ÉB, Falcão AB, et al. Clozapine for Severe Treatment-Resistant Disruptive Behaviors in Youth with Autism Spectrum Disorder: A Prospective Real-World Interventional Study. Journal of Child and Adolescent Psychopharmacology. 2026;36(10):617-630. doi:10.1177/10445463261467155
BibTeX
@article{daRosa2026,
author = {da Rosa, André Luiz Schuh Teixeira and Sorato, Gabriela Bezerra and Manjabosco, Felipe and Dellazari, Lucas and de Bem, Érica Bonganhi and Falcão, Arthur Bezerra and Cia, Lucas de Oliveira and Nedel, Ana Júlia Limberger and da Costa, Marina Ribeiro Barreto and Bezerra, Olivia Sorato and Borges, Rogério Boff and Rohde, Luis Augusto and Graeff-Martins, Ana Soledade},
title = {Clozapine for Severe Treatment-Resistant Disruptive Behaviors in Youth with Autism Spectrum Disorder: A Prospective Real-World Interventional Study},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2026},
volume = {36},
number = {10},
pages = {617--630},
doi = {10.1177/10445463261467155}
}
EUVIMED